SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Parkhomenko Elena) "

Sökning: WFRF:(Parkhomenko Elena)

  • Resultat 1-9 av 9
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Huckins, Laura M., et al. (författare)
  • Gene expression imputation across multiple brain regions provides insights into schizophrenia risk
  • 2019
  • Ingår i: Nature genetics. - 1546-1718. ; 51:4, s. 659-
  • Tidskriftsartikel (refereegranskat)abstract
    • Transcriptomic imputation approaches combine eQTL reference panels with large-scale genotype data in order to test associations between disease and gene expression. These genic associations could elucidate signals in complex genome-wide association study (GWAS) loci and may disentangle the role of different tissues in disease development. We used the largest eQTL reference panel for the dorso-lateral prefrontal cortex (DLPFC) to create a set of gene expression predictors and demonstrate their utility. We applied DLPFC and 12 GTEx-brain predictors to 40,299 schizophrenia cases and 65,264 matched controls for a large transcriptomic imputation study of schizophrenia. We identified 413 genic associations across 13 brain regions. Stepwise conditioning identified 67 non-MHC genes, of which 14 did not fall within previous GWAS loci. We identified 36 significantly enriched pathways, including hexosaminidase-A deficiency, and multiple porphyric disorder pathways. We investigated developmental expression patterns among the 67 non-MHC genes and identified specific groups of pre- and postnatal expression.
  •  
2.
  • Marshall, Christian R., et al. (författare)
  • Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects
  • 2017
  • Ingår i: Nature Genetics. - 1061-4036. ; 49:1, s. 27-35
  • Tidskriftsartikel (refereegranskat)abstract
    • Copy number variants (CNVs) have been strongly implicated in the genetic etiology of schizophrenia (SCZ). However, genome-wide investigation of the contribution of CNV to risk has been hampered by limited sample sizes. We sought to address this obstacle by applying a centralized analysis pipeline to a SCZ cohort of 21,094 cases and 20,227 controls. A global enrichment of CNV burden was observed in cases (odds ratio (OR) = 1.11, P = 5.7 x 10(-15)), which persisted after excluding loci implicated in previous studies (OR = 1.07, P = 1.7 x 10(-6)). CNV burden was enriched for genes associated with synaptic function (OR = 1.68, P = 2.8 x 10(-11)) and neurobehavioral phenotypes in mouse (OR = 1.18, P = 7.3 x 10(-5)). Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by nonallelic homologous recombination.
  •  
3.
  • Papp, Zoltan, et al. (författare)
  • Levosimendan: Molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan
  • 2012
  • Ingår i: International Journal of Cardiology. - Elsevier. - 0167-5273. ; 159:2, s. 82-87
  • Forskningsöversikt (refereegranskat)abstract
    • The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K+ channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K+ channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
  •  
4.
  • Ripke, Stephan, et al. (författare)
  • Biological insights from 108 schizophrenia-associated genetic loci
  • 2014
  • Ingår i: Nature. - 0028-0836. ; 511:7510, s. 421-427
  • Tidskriftsartikel (refereegranskat)abstract
    • Schizophrenia is a highly heritable disorder. Genetic risk is conferred by a large number of alleles, including common alleles of small effect that might be detected by genome-wide association studies. Here we report a multi-stage schizophrenia genome-wide association study of up to 36,989 cases and 113,075 controls. We identify 128 independent associations spanning 108 conservatively defined loci that meet genome-wide significance, 83 of which have not been previously reported. Associations were enriched among genes expressed in brain, providing biological plausibility for the findings. Many findings have the potential to provide entirely new insights into aetiology, but associations at DRD2 and several genes involved in glutamatergic neurotransmission highlight molecules of known and potential therapeutic relevance to schizophrenia, and are consistent with leading pathophysiological hypotheses. Independent of genes expressed in brain, associations were enriched among genes expressed in tissues that have important roles in immunity, providing support for the speculated link between the immune system and schizophrenia.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • Yilmaz, Mehmet B, et al. (författare)
  • Renal Effects of Levosimendan: A Consensus Report.
  • 2013
  • Ingår i: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. - 1573-7241.
  • Tidskriftsartikel (refereegranskat)abstract
    • Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards the mechanism of action, the opening of mitochondrial KATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).
  •  
9.
  • Yilmaz, Mehmet B., et al. (författare)
  • Renal Effects of Levosimendan A Consensus Report
  • 2013
  • Ingår i: Cardiovascular Drugs and Therapy. - 0920-3206 .- 1573-7241. ; 27:6, s. 581-590
  • Forskningsöversikt (övrigt vetenskapligt)abstract
    • Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards the mechanism of action, the opening of mitochondrial K-ATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).
Skapa referenser, mejla, bekava och länka
  • Resultat 1-9 av 9
Åtkomst
fritt online (1)
Typ av publikation
tidskriftsartikel (7)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (8)
övrigt vetenskapligt (1)
Författare/redaktör
Filippatos, Gerasimo ... (4)
Atar, Dan, (3)
Cohen, David, (3)
Bergen, Sarah E (3)
Katus, Hugo A (3)
Mattheisen, Manuel, (3)
visa fler...
Agartz, Ingrid, (3)
Andreassen, Ole A., (3)
Buckner, Randy L., (3)
Cahn, Wiepke, (3)
Cichon, Sven, (3)
Corvin, Aiden, (3)
Djurovic, Srdjan, (3)
Donohoe, Gary, (3)
Ikeda, Masashi, (3)
Jonsson, Erik G., (3)
Kahn, Rene S., (3)
McDonald, Colm, (3)
McIntosh, Andrew M., (3)
Melle, Ingrid, (3)
Morris, Derek W., (3)
Ophoff, Roel A., (3)
Rietschel, Marcella, (3)
Roffman, Joshua L., (3)
Smoller, Jordan W., (3)
Adolfsson, Rolf, (3)
Pollesello, Piero (3)
Magnusson, Patrik K ... (3)
Salomaa, Veikko (3)
Paunio, Tiina (3)
Eriksson, Johan (3)
Armstrong, Paul W. (3)
Powell, John (3)
Del-Favero, Jurgen (3)
Parkhomenko, Alexand ... (3)
Ohman, E. Magnus, (3)
White, Harvey D., (3)
Esko, Tonu (3)
Levinson, Douglas F. (3)
Shi, Jianxin (3)
Duan, Jubao (3)
Freimer, Nelson B. (3)
Sanders, Alan R. (3)
Gejman, Pablo V. (3)
Nieminen, Markku S. (3)
Metspalu, Andres (3)
Visscher, Peter M. (3)
Hirschhorn, Joel N. (3)
Édes, István (3)
Degenhardt, Franzisk ... (3)
visa färre...
Lärosäte
Uppsala universitet (4)
Karolinska Institutet (4)
Umeå universitet (3)
Göteborgs universitet (1)
Lunds universitet (1)
Språk
Engelska (9)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (9)
Naturvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy